Typhoid medicine referance details

Reading Document
Medical Text Search

typhoid fever treatment antibiotics management

Medical Text Search

Salmonella typhi diagnosis clinical features complications

GradeResponse
GradeResponse
Here is a comprehensive typhoid fever medicine reference:

Typhoid Fever — Medical Reference

Overview

Typhoid fever (enteric fever) is caused by Salmonella enterica serotype Typhi, and paratyphoid fever by S. Paratyphi A, B, or C. It is transmitted via the fecal-oral route, typically through contaminated food or water.

Clinical Features

PhaseTimelineFeatures
Incubation10–20 daysAsymptomatic
Week 1OnsetFever (stepwise rise), headache, malaise, relative bradycardia
Week 2ProgressionAbdominal pain/distension, diarrhea or constipation, splenomegaly, rose spots (abdominal vasculitic rash)
Week 3+ComplicationsIntestinal hemorrhage, perforation, paralytic ileus, cholecystitis
(Bailey & Love's Surgery, 28th Ed., p. 1387)

Diagnosis

  • Blood culture — gold standard (positive in ~60–80% in week 1)
  • Bone marrow culture — highest sensitivity (~90%), even after antibiotics started
  • Stool/urine culture — positive in later weeks
  • Widal test — suggestive but low specificity; rising titers more meaningful
  • CBC: relative leukopenia, anemia, thrombocytopenia
  • LFTs: mildly elevated transaminases

Antibiotic Treatment

(Harrison's Principles of Internal Medicine, 21st Ed., p. 4861)

First-Line Agents

AntibioticDoseDurationNotes
Ceftriaxone2–3 g IV/IM once daily10–14 daysDrug of choice in endemic regions (India, Nepal, Africa) with DSC/MDR strains
Azithromycin500 mg–1 g orally daily7 daysPreferred for uncomplicated typhoid; good oral bioavailability
Ciprofloxacin500 mg orally twice daily OR 400 mg IV twice daily10–14 daysOnly for confirmed quinolone-susceptible strains
Ofloxacin400 mg orally twice daily7–10 daysEffective for quinolone-susceptible strains
⚠️ Important: Fluoroquinolones should NOT be used empirically in the Indian subcontinent, Nepal, or parts of Africa due to high prevalence of strains with decreased susceptibility to ciprofloxacin (MIC >0.125 µg/mL). (Harrison's, p. 4861)

Multidrug-Resistant (MDR) Typhoid (resistant to Ampicillin, Chloramphenicol, Co-trimoxazole)

AntibioticDoseDuration
Ceftriaxone2–3 g IV daily10–14 days
Azithromycin1 g orally daily5–7 days

Extensively Drug-Resistant (XDR) Typhoid (also resistant to fluoroquinolones + 3rd-gen cephalosporins)

AntibioticDoseNotes
Meropenem1 g IV every 8 hoursDrug of choice for XDR
Azithromycin1 g orally dailyIf susceptible

Older Agents (for Fully Susceptible Strains Only)

AntibioticDoseDuration
Chloramphenicol500 mg orally 4× daily14 days
Ampicillin750–1000 mg orally 4× daily14 days
Co-trimoxazole (TMP-SMX)160/800 mg orally twice daily14 days

Special Populations

GroupRecommendation
ChildrenCeftriaxone 60 mg/kg/day IV or Azithromycin 20 mg/kg/day orally
Pregnant womenCeftriaxone preferred; avoid fluoroquinolones and chloramphenicol
Severe/complicated typhoidIV Ceftriaxone + Dexamethasone (for altered consciousness or shock)

Surgical Complications & Management

(Bailey & Love's, p. 1387)
  • Intestinal perforation — emergency laparotomy; most common in 3rd week
  • GI hemorrhage — transfusion + surgical intervention if uncontrolled
  • Paralytic ileus — conservative (NG suction, IV fluids)
  • Cholecystitis — cholecystectomy may be needed (typhoid carriers)

Chronic Carriage

  • Defined as fecal excretion of S. Typhi >1 year
  • Treatment: Ciprofloxacin 750 mg twice daily × 4 weeks (if quinolone-sensitive) or Ampicillin + Probenecid
  • Cholecystectomy considered in gallbladder carriers unresponsive to antibiotics

Vaccination

VaccineTypeRouteDuration
Ty21a (Vivotif)Live attenuated oralOral5–7 years
Vi polysaccharide (Typhim Vi)InjectableIM~3 years
Vi-conjugate (Typbar-TCV)Conjugate injectableIMLonger; preferred in children ≥6 months

Key Takeaway

  • Azithromycin or Ceftriaxone are the current empirical treatments of choice in most endemic regions.
  • Always check local susceptibility patterns before prescribing fluoroquinolones.
  • Prompt treatment reduces mortality to <1%. (Harrison's, 21st Ed., p. 4861)
This is a shared conversation. Sign in to Orris to start your own chat.